No Increase in Second Tumors after Cytotoxic Chemotherapy for Gestational Trophoblastic Tumors

New England Journal of Medicine

Volumn 308, Issue 9, 1983, Pages 473-476

  Rustin, Gordon J S ^a   Rustin, Frances ^a   Dent, Joan ^a   Booth, Margaret ^a   Salt, Sandra ^a   Bagshawe, Kenneth D ^a  

^a CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZAURIDINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; FOLINATE CALCIUM; HYDROXYUREA; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; VINBLASTINE; VINCRISTINE;

CANCER CHEMOTHERAPY; CHEMICAL CARCINOGENESIS; CHORIOCARCINOMA; CLINICAL ARTICLE; FEMALE GENITAL SYSTEM; HUMAN; INVASIVE MOLE; PREGNANCY; THERAPY;

EID: 0020684901     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198303033080901     Document Type: Article

References (28)

1. Canellos GP, DeVita VT, Arseneau JC, Whang-Peng J, Johnson REC. Second malignancies complicating Hodgkin's disease in remission. Lancet. 1975; 1: 947–9.
2. Krikorian JG, Burke JS, Rosenberg SA, Kaplan HS. Occurrence of non-Hodgkin's lymphoma after therapy for Hodgkin's disease. N Engl J Med. 1979; 300: 452–8.
3. Stott H, Fox W, Girling DJ, Stephens RJ, Galton DAG. Acute leukaemia after busulphan. Br Med J. 1977; 2: 1513–7.
4. Reimer RR, Hoover R, Fraumeni JF Jr, Young RC. Acute leukemia after alkylating-agent therapy of ovarian cancer. N Engl J Med. 1977; 297: 177–81.
5. Casciato DA, Scott JL. Acute leukemia following prolonged cytotoxic agent therapy. Medicine (Baltimore). 1979; 58: 32–46.
6. Berk PD, Goldberg JD, Silverstein MN, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med. 1981; 304: 441–7.
7. Bagshawe KD. Lessons from choriocarcinoma. Proc R Soc Med. 1977; 70: 303–6.
8. Lewis JL Jr. Treatment of metastatic gestational trophoblastic neoplasms: a brief review of developments in the years 1968 to 1978. Am J Obstet Gynecol. 1980; 136: 163–72.
9. Rustin GJS, Bagshawe KD, Newlands ES, Begent RHJ. Cytotoxic drugs and sterility. Lancet. 1981; 1: 1316.
10. Bagshawe KD. Risk and prognostic factors in trophoblastic neoplasia. Cancer. 1976; 38: 1373–85.
11. Bagshawe KD, Begent RHJ. Trophoblastic tumours: clinical features and management. In: Coppleson M, ed. Gynecologic oncology. Edinburgh: Churchill Livingstone, 1981:757–72.
12. Werner B. New methods for surveying health risks at work. Stat News. 1979; 47: 23–7.
13. Waterhouse J, Muir C, Correa P, Powell J. eds. Cancer incidence in five continents. Vol. 3. Lyon: International Agency for Research on Cancer, 1976. (IARC scientific publication no. 15).
14. Bailar JC. Ederer F. Significant factors for the ratio of a Poisson variable to its expectation. Biometrics. 1964; 20: 639–43.
15. Penn I. Occurrence of cancer in immune deficiencies. Cancer. 1974; 34: 858–66.
16. Moertel CG, Dockerty MB, Baggenstoss AH. Multiple primary malignant neoplasms. III. Tumours of multicentric origin. Cancer. 1961; 14: 238–48.
17. Bailar JC III. The incidence of independent tumors among uterine cancer patients. Cancer. 1963; 16: 842–53.
18. Rustia M, Shubik P. Life-span carcinogenicity tests with 4-amino-N10-methylpteroylglutamic acid (methotrexate) in Swiss mice and Syrian golden hamsters. Toxicol Appl Pharmacol. 1973; 26: 329–38.
19. Weisburger EK. Bioassay program for carcinogenic hazards of cancer chemotherapeutic agents. Cancer. 1977; 40: 1935–49.
20. Ryan TJ, Boddington MM, Spriggs AI. Chromosomal abnormalities produced by folic acid antagonists. Br J Dermatol. 1965; 77: 541–55.
21. Jensen MK, Nyfors A. Cytogenetic effect of methotrexate on human cells in vivo: comparison between results obtained by chromosome studies on bone-marrow cells and blood lymphocytes and by the micronucleus test. Mutat Res. 1979; 64: 339–43.
22. Marquardt H, Marquardt H. Induction of malignant transformation and mutagenesis in cell cultures by cancer chemotherapeutic agents. Cancer. 1977; 40: 1930–4.
23. International Agency for Research on Cancer. IARC monograph on the evaluation of the carcinogenic risk of chemicals to humans. Vol. 26. Some antineoplastic and immunosuppressive agents. Lyon: International Agency for Research on Cancer, 1981:267–92.
24. Bailin PL, Tindall JP, Roenigk HH Jr, Hogan MD. Is methotrexate therapy for psoriasis carcinogenic?: a modified retrospective-prospective analysis. JAMA. 1975; 232: 359–62.
25. Barich LL, Schwartz J, Barich D. Oral methotrexate in mice: a co-carcinogenic as well as an anti-tumour agent to methylchlolanthrene-induced cutaneous tumors. J Invest Dermatol. 1962; 39: 615–9.
26. Kinlen LJ, Sheil AGR, Peto J, Doll R. Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs. Br Med J, 1979; 2: 1461–6.
27. Kinlen LJ, Peto J, Doll R, Sheil AGR. Cancer in patients treated with immunosuppressive drugs. Br Med J, 1981; 282: 474.
28. Bonadonna G, Brusamolino E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med. 1976; 294: 405–10.